Literature DB >> 15384027

Histologic evolution of bone disease 6 months after successful kidney transplantation.

Elisa A S Cruz1, Jocemir R Lugon, Vanda Jorgetti, Sergio A Draibe, Aluizio B Carvalho.   

Abstract

BACKGROUND: The histologic patterns of bone disease, as well as the evolution of renal osteodystrophy after kidney transplantation (Tx), are not well defined. Information in this regard is scarce and contradictory.
METHODS: Before and 6 months after Tx, analysis of biochemical, hormonal, and bone histomorphometric parameters were performed. Twenty patients (14 men and 6 women) entered the study. Median age was 36.5 (range, 20 to 55) years, and median time on dialysis was 22 (9 to 88) months.
RESULTS: Bone histomorphometric diagnoses at pre-Tx were adynamic bone disease, 12; mixed bone disease, 3; mild disease, 3; and osteitis fibrosa, 2. After Tx, 11 had adynamic bone disease; 8, mild disease; and 1, osteomalacia. As a whole, dynamic parameters improved significantly in patients who had adynamic bone. Five of the 12 with this diagnosis completely recovered their bone turnover. Pre-Tx hyperparathyroidism bone features improved or resolved, but 5 of the 8 patients had low-turnover bone disease (adynamic disease, 4; osteomalacia, 1). Three of them had persistence of aluminum and/or iron deposits on bone surface, and the other 2 had hypophosphatemia and high intact parathyroid hormone levels. Overall, biochemical parameters tended toward normalization. Serum intact parathyroid hormone before Tx was correlated negatively with post-Tx trabecular thickness.
CONCLUSION: Six months after Tx, bone histology remained abnormal. The high turnover bone disease improved in all cases, but in most of them low turnover bone disease emerged. Nearly half of the cases with pre-Tx adynamic bone disease recovered their bone turnover completely with some improvement observed in the majority of the remaining cases.

Entities:  

Mesh:

Year:  2004        PMID: 15384027

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  19 in total

Review 1.  Tertiary excess of fibroblast growth factor 23 and hypophosphatemia following kidney transplantation.

Authors:  Wacharee Seeherunvong; Myles Wolf
Journal:  Pediatr Transplant       Date:  2010-10-08

Review 2.  Bone Disease after Kidney Transplantation.

Authors:  Antoine Bouquegneau; Syrazah Salam; Pierre Delanaye; Richard Eastell; Arif Khwaja
Journal:  Clin J Am Soc Nephrol       Date:  2016-02-15       Impact factor: 8.237

Review 3.  Metabolic bone diseases in kidney transplant recipients.

Authors:  Rubin Zhang; Kanwaljit K Chouhan
Journal:  World J Nephrol       Date:  2012-10-06

Review 4.  Osteoporosis after renal transplantation.

Authors:  Evangelia Dounousi; Konstantinos Leivaditis; Theodoros Eleftheriadis; Vassilios Liakopoulos
Journal:  Int Urol Nephrol       Date:  2014-11-11       Impact factor: 2.370

Review 5.  Management of mineral and bone disorder after kidney transplantation.

Authors:  Kamyar Kalantar-Zadeh; Miklos Z Molnar; Csaba P Kovesdy; Istvan Mucsi; Suphamai Bunnapradist
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-07       Impact factor: 2.894

Review 6.  Clinical practice. Fibroblast growth factor (FGF)23: a new hormone.

Authors:  Uri S Alon
Journal:  Eur J Pediatr       Date:  2010-12-31       Impact factor: 3.183

7.  Changes in Bone Histomorphometry after Kidney Transplantation.

Authors:  Satu Keronen; Leena Martola; Patrik Finne; Inari S Burton; Heikki Kröger; Eero Honkanen
Journal:  Clin J Am Soc Nephrol       Date:  2019-05-14       Impact factor: 8.237

8.  Micro-MR imaging-based computational biomechanics demonstrates reduction in cortical and trabecular bone strength after renal transplantation.

Authors:  Chamith S Rajapakse; Mary B Leonard; Yusuf A Bhagat; Wenli Sun; Jeremy F Magland; Felix W Wehrli
Journal:  Radiology       Date:  2012-03       Impact factor: 11.105

Review 9.  Bone and mineral disorders after kidney transplantation: therapeutic strategies.

Authors:  Miklos Z Molnar; Mohamed S Naser; Connie M Rhee; Kamyar Kalantar-Zadeh; Suphamai Bunnapradist
Journal:  Transplant Rev (Orlando)       Date:  2013-12-12       Impact factor: 3.943

10.  Comparison of the clinical effectiveness and safety between the use of denosumab vs bisphosphonates in renal transplant patients.

Authors:  H McKee; G Ioannidis; A Lau; D Treleaven; A Gangji; C Ribic; M Wong-Pack; A Papaioannou; J D Adachi
Journal:  Osteoporos Int       Date:  2020-01-03       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.